Merger Scrutiny A Bigger Risk To Pharma Than Drug Price Reform, Orzag Predicts

 
• By Jessica Merrill
  
US M&A scrutiny could be an overhang for pharma • Source: Alamy
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Pricing Debate

More from Market Access